Generics in Europe
Summary
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The European generics market had total revenues of $74.8bn in 2019, representing a compound annual growth rate (CAGR) of 6.9% between 2015 and 2019.
- Market consumption volume increased with a CAGR of 2.2% between 2015 and 2019, to reach a total of 56.1% in 2019.
- Germany and the UK have some of the highest generic market shares globally but there is still potential for growth in other countries with a lower share, such as Italy with just 22.2%, or Turkey with 63.9%.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
- What was the size of the Europe generics market by value in 2019?
- What will be the size of the Europe generics market in 2024?
- What factors are affecting the strength of competition in the Europe generics market?
- How has the market performed over the last five years?
- How large is Europe’s generics market in relation to its regional counterparts?
- 1 Executive Summary
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Market rivalry
- 1.7. Competitive Landscape
- 2 Market Overview
- 2.1. Market definition
- 2.2. Market analysis
- 3 Market Data
- 3.1. Market value
- 3.2. Market volume
- 4 Market Segmentation
- 4.1. Geography segmentation
- 5 Market Outlook
- 5.1. Market value forecast
- 5.2. Market volume forecast
- 6 Five Forces Analysis
- 6.1. Summary
- 6.2. Buyer power
- 6.3. Supplier power
- 6.4. New entrants
- 6.5. Threat of substitutes
- 6.6. Degree of rivalry
- 7 Competitive Landscape
- 7.1. Who are the leading players?
- 7.2. What are the strengths of the leading players?
- 7.3. How has the outbreak of COVID-19 impacted leading players?
- 8 Company Profiles
- 8.1. Teva Pharmaceutical Industries Limited
- 8.2. Mylan N.V.
- 8.3. Pfizer Inc.
- 8.4. Sanofi SA
- 9 Macroeconomic Indicators
- 9.1. Country data
- 10 Appendix
- 10.1. Methodology
- 10.2. Industry associations
- 10.3. Related MarketLine research
- 10.4. About MarketLine
- List of Tables
- Table 1: Europe generics market value: $ billion, 2015-19
- Table 2: Europe generics market volume: % of total pharma, 2015-19
- Table 3: Europe generics market geography segmentation: $ billion, 2019
- Table 4: Europe generics market value forecast: $ billion, 2019-24
- Table 5: Europe generics market volume forecast: % of total pharma, 2019-24
- Table 6: Teva Pharmaceutical Industries Limited: key facts
- Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
- Table 8: Teva Pharmaceutical Industries Limited: Key Employees
- Table 9: Mylan N.V.: key facts
- Table 10: Mylan N.V.: Annual Financial Ratios
- Table 11: Mylan N.V.: Key Employees
- Table 12: Pfizer Inc.: key facts
- Table 13: Pfizer Inc.: Annual Financial Ratios
- Table 14: Pfizer Inc.: Key Employees
- Table 15: Pfizer Inc.: Key Employees Continued
- Table 16: Sanofi SA: key facts
- Table 17: Sanofi SA: Annual Financial Ratios
- Table 18: Sanofi SA: Key Employees
- Table 19: Sanofi SA: Key Employees Continued
- Table 20: Europe size of population (million), 2015-19
- Table 21: Europe gdp (constant 2005 prices, $ billion), 2015-19
- Table 22: Europe gdp (current prices, $ billion), 2015-19
- Table 23: Europe inflation, 2015-19
- Table 24: Europe consumer price index (absolute), 2015-19
- Table 25: Europe exchange rate, 2015-19
- List of Figures
- Figure 1: Europe generics market value: $ billion, 2015-19
- Figure 2: Europe generics market volume: % of total pharma, 2015-19
- Figure 3: Europe generics market geography segmentation: % share, by value, 2019
- Figure 4: Europe generics market value forecast: $ billion, 2019-24
- Figure 5: Europe generics market volume forecast: % of total pharma, 2019-24
- Figure 6: Forces driving competition in the generics market in Europe, 2019
- Figure 7: Drivers of buyer power in the generics market in Europe, 2019
- Figure 8: Drivers of supplier power in the generics market in Europe, 2019
- Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2019
- Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2019
- Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2019
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook